Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.20.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (1,179) $ (4,617)
Loss (income) from discontinuing operations (8) 2,881
Loss from continuing operations (1,187) (1,736)
Adjustments to reconcile net loss to net cash used in operating activities, continuing operations:    
Depreciation 52 14
Amortization 79 82
Stock-based compensation 58 119
Change in fair value of warrant liability, acquisition note payable and other derivatives (131) (24)
Amortization of operating lease right-of-use assets 10 49
Change in fair value of siParadigm Earn-Out (24) 0
Amortization of discount on debt and debt issuance costs 36 467
Interest added to Convertible Note 0 89
Changes in:    
Accounts receivable (183) (103)
Other current assets 110 77
Other non-current assets (4) (1)
Accounts payable, accrued expenses and deferred revenue 130 (109)
Due to Interpace Biosciences, Inc. 1,200 0
Obligations under operating leases (21) (60)
Net cash provided by (used in) operating activities, continuing operations 125 (1,136)
Net cash used in operating activities, discontinuing operations (289) (3,328)
Net cash used in operating activities (164) (4,464)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets 0 (19)
Net cash provided by (used in) investing activities, continuing operations 0 (19)
Net cash provided by (used in) investing activities, discontinuing operations 28 (13)
Net cash provided by (used in) investing activities 28 (32)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on obligations under finance leases (13) (10)
Proceeds from offerings of common stock, net of certain offering costs 0 5,412
Payments on Advance from NovellusDx, Ltd. (150) 0
Net cash provided by (used in) financing activities, continuing operations (163) 5,402
Net cash used in financing activities, discontinuing operations 0 (291)
Net cash provided by (used in) financing activities (163) 5,111
Effect of foreign exchange rates on cash and cash equivalents and restricted cash 12 (79)
Net increase (decrease) in cash and cash equivalents and restricted cash (287) 536
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH    
Beginning 4,230 511
Ending 3,943 1,047
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED    
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH 3,943 1,047
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 7 304
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Common stock issued in VentureEast settlement $ 12 $ 0